EVALUATION OF PHENYLBUTAZONE (BUTAZOLIDIN) IN THE TREATMENT OF RHEUMATOID SPONDYLITIS: REPORT OF 50 CASES
Authors: E C TOONE, W R IRBY
Journal: Annals of Internal Medicine (1954)

Article1 July 1954EVALUATION OF PHENYLBUTAZONE (BUTAZOLIDIN) IN THE TREATMENT OF RHEUMATOID SPONDYLITIS: REPORT OF 50 CASESELAM C. TOONE JR., M.D., F.A.C.P., W. ROBERT IRBY, M.D.ELAM C. TOONE JR., M.D., F.A.C.P., W. ROBERT IRBY, M.D.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-41-1-70 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptIn recent months much information has accumulated concerning the therapeutic effects and toxic potentialities of a new synthetic "antirheumatic" agent, phenylbutazone, commercially known as Butazolidin. This drug was first synthesized by H. Stenzl, of Basel, Switzerland, in 1946. It is a pyrazol whose chemical designation is sodium-4-butyl-1, 2 diphenyl-3,5-pyrazolidinedione⌖. Originally it was used in Europe as a solvent for aminopyrine in a preparation known as Irgapyrin, administered by intramuscular injection. In this country the phenylbutazone component has been used alone for the most part, and administered orally. A number of observers have found it to be quite helpful in the...Bibliography1. Belart W: Irgapyrin, the antirheumatic remedy, Schweiz. med. Wchnschr. 79: 582, 1949. MedlineGoogle Scholar2. GsellMuller OW: Parenteral Pyramidon-pyrazolidine treatment of rheumatism and infections by means of Irgapyrin, Schweiz. med. Wchnschr. 80: 310, 1950. Google Scholar3. Wilhelmi G: The pharmacologic properties of Irgapyrin, a new compound of the pyrazol series, Schweiz. med. Wchnschr. 79: 577, 1949. MedlineGoogle Scholar4. CurrieBrownWill JPRAG: Observations on the treatment of rheumatoid arthritis with Butazolidin, Ann. Rheumat. Dis. 12: 88 (June) 1953. CrossrefMedlineGoogle Scholar5. MacknightIrbyToone JCREC: Phenylbutazone in management of rheumatoid arthritis, rheumatoid spondylitis, and gouty arthritis, Geriatrics 9: 111 (Mar.) 1954. MedlineGoogle Scholar6. KuzellSchaffarzickNauglerGaudinMankle WCRWWEGEA: Phenylbutazone—a further clinical evaluation. Read before the Annual Meeting of the American Rheumatism Association, May 28, 1953. Google Scholar7. KuzellSchaffarzick WCRW: Phenylbutazone (Butazolidin) and butopyrin, a study of clinical effects in arthritis and gout, California Med. 77: 319, 1952. MedlineGoogle Scholar8. SteinbrockerBerkowitzCarpEhrlichElkind OSSMM: Phenylbutazone therapy of arthritis and other painful musculoskeletal disorders, J. A. M. A. 150: 1087-1091 (Nov. 15) 1952. CrossrefMedlineGoogle Scholar9. KiddBoyceFreyberg EGKCRH: Clinical studies of phenylbutazone (Butazolidin) and butapyrin in rheumatoid arthritis, rheumatoid spondylitis and gout, Ann. Rheumat. Dis. 12: 20, 1953. CrossrefMedlineGoogle Scholar10. SmithKunz CHHG: Butazolidin in rheumatoid disorders, J. M. Soc. New Jersey 49: 306 (July) 1952. MedlineGoogle Scholar11. PattersonBensonSchoenberg RMJSPL: Clinical evaluation of phenylbutazone, U. S. Armed Forces M. J. 4: 109, 1953. MedlineGoogle Scholar12. KielyStickney JMJM: Agranulocytosis caused by phenylbutazone and 4-amino-antipyrine, Proc. Staff Meet., Mayo Clin. 28: 12 (June 17) 1953. Google Scholar13. EtessJacobson ADAS: Fatality due to agranulocytosis following the use of phenylbutazone (Butazolidin), J. A. M. A. 151: 639 (Feb. 21) 1953. CrossrefMedlineGoogle Scholar14. SteinbergBohrodRoodenburg CLMGAI: Agranulocytosis following phenylbutazone (Butazolidin) therapy, report of a fatal case, J. A. M. A. 152: 33 (May 2) 1953. CrossrefMedlineGoogle Scholar15. ShieldsAdamsonMacGregor WENEJB: Peptic ulcer perforation following administration of phenylbutazone, J. A. M. A. 152: 28 (May 2) 1953. CrossrefMedlineGoogle Scholar16. Raffensberger EC: Multiple gastric ulcers occurring during phenylbutazone therapy, J. A. M. A. 152: 30 (May 2) 1953. CrossrefMedlineGoogle Scholar17. Krainin P: Gastric ulcer with massive hemorrhage following use of phenylbutazone, J. A. M. A. 152: 31 (May 2) 1953. CrossrefMedlineGoogle Scholar18. StephensYeomanHolbrookHillGoodwin CAEEWPDFWL: Benefits and toxicity of phenylbutazone (Butazolidin) in rheumatoid arthritis, J. A. M. A. 150: 1084 (Nov. 15) 1952. CrossrefMedlineGoogle Scholar19. WilkinsonBrown ELH: The effect of Butazolidin (phenylbutazone) on water and electrolyte excretion, Am. J. M. Sc. 225: 153, 1953. CrossrefMedlineGoogle Scholar20. Granier LW: Untoward effects of phenylbutazone (Butazolidin), J. A. M. A. 150: 1332 (Nov. 29) 1952. CrossrefGoogle Scholar21. DaviesBarterGeeHirson HRRWAC: Observations on the use of Butazolidin in arthritis, Brit. M. J. 2: 1392 (Dec. 27) 1952. CrossrefMedlineGoogle Scholar22. ByronOrenstein CMHB: Clinical evaluation of phenylbutazone, a new antiarthritic agent, New York State J. Med. 53: 676, 1953. MedlineGoogle Scholar23. EnglemanKruppRinehartFineBruckBarbourFarquharJones EPMAJFMELABJWRC: Uncommon and serious reactions to phenylbutazone—a clinico-pathologic study. Read before the Annual Meeting of the American Rheumatism Association, May 28, 1953. Google Scholar24. SmythFreybergLampe CJRHI: Roentgen therapy for rheumatoid arthritis of the spine, J. A. M. A. 117: 826, 1941. CrossrefGoogle Scholar25. Toone EC: Rheumatoid spondylitis, Ann. Int. Med. 30: 733, 1949. LinkGoogle Scholar26. GrahamFletcherGraham DCAAW: The natural course of ankylosing (Marie-Strümpell) spondylitis and its response to treatment, Postgraduate Medicine and Surgery: Rheumatic Diseases, 1952, W. B. Saunders Co., Philadelphia, pp. 83-87. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Richmond, Virginia*Received for publication December 7, 1953.From the Department of Medicine, Medical College of Virginia, and the Medical Service, McGuire Veterans Hospital, Richmond, Virginia.Presented at the meeting of the American Clinical and Climatological Association, Hot Springs, Virginia, November 2, 1953.Published with the permission of the Chief Medical Director, Departments of Medicine and Surgery, Veterans Administration, who assumes no responsibility for the opinions expressed or conclusions drawn by the authors.†Trainee, National Institute of Arthritis and Metabolic Diseases. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byCardiovascular risk of non-steroidal anti-inflammatory drugsAnkylosing SpondylitisAbortionAnkylosing Spondylitis: Recent Advances in Diagnosis and TreatmentAnkylosing SpondylitisRHEUMATISM AND ARTHRITIS: REVIEW OF AMERICAN AND ENGLISH LITERATURE OF RECENT YEARS (TWELFTH RHEUMATISM REVIEW)* Part IICHARLEY J. SMYTH, M.D., F.A.C.P., JOSEPH J. BUNIM, M.D., F.A.C.P., WILLIAM S. CLARK, M.D., F.A.C.P., DARRELL C. CRAIN, M.D., F.A.C.P., FELIX E. DEMARTINI, M.D., IVAN F. DUFF, M.D., F.A.C.P., EPHRAIM P. ENGLEMAN, M.D., F.A.C.P., DONALD C. GRAHAM, M.D., F.R.C.P. (C), MAX M. MONTGOMERY, M.D., F.A.C.P., BERNARD M. NORCROSS, M.D., F.A.C.P., HOWARD F. POLLEY, MARIAN W. ROPES, M.D., F.A.C.P., EDWARD F. ROSENBERG, M.D., F.A.C.P.The Toxic Effects of Phenylbutazone (Butazolidin)Phenylbutazone (Butazolidin)—Studies on the Stimulation of Gastric Secretion and the Formation of Peptic Ulcer in Man 1 July 1954Volume 41, Issue 1Page: 70-78KeywordsAnkylosing spondylitisArthritisDrug synthesisDrugsHospital medicineIntramuscular injectionsMedical servicesMetabolic disordersSurgery ePublished: 1 December 2008 Issue Published: 1 July 1954 PDF downloadLoading ...